Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real-world study in Quebec.

British journal of haematology·2026
Same author

Impact of Pharmacist-Provided Education Using New Information Sheets on Activation in Patients Treated with Oral Antineoplastic Drugs (IMPACT-OAD Project).

The Canadian journal of hospital pharmacy·2023
Same author

Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2022
Same author

Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges.

Clinical trials (London, England)·2022
Same author

Effect of mannitol on acute kidney injury induced by cisplatin.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2020
Same author

Opinion, experience and educational preferences concerning pharmacogenomics: an exploratory study of Quebec pharmacists.

Pharmacogenomics·2020
Same journal

Successful oral desensitization to temozolomide in a patient with immediate hypersensitivity reaction.

Cancer chemotherapy and pharmacology·2026
Same journal

Pharmacokinetics of asciminib in a patient with chronic myeloid leukemia undergoing maintenance hemodialysis.

Cancer chemotherapy and pharmacology·2026
Same journal

Off-target anti-leukemic effects of antibiotics: mechanisms and therapeutic insights.

Cancer chemotherapy and pharmacology·2026
Same journal

The use of pharmacodynamic results for recommended phase II decision making in oncology clinical trials.

Cancer chemotherapy and pharmacology·2026
Same journal

Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.

Cancer chemotherapy and pharmacology·2026
Same journal

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.

Cancer chemotherapy and pharmacology·2026
See all related articles

Related Experiment Video

Updated: May 26, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Going past the data for temozolomide.

J Lee Villano1, Nathalie Letarte, Linda R Bressler

  • 1Department of Medicine, Section of Hematology/Oncology, University of Illinois at Chicago, 840 S Wood St Rm 839, M/C 713, Chicago, IL 60612, USA. jvillano@uic.edu

Cancer Chemotherapy and Pharmacology
|December 8, 2011
PubMed
Summary
This summary is machine-generated.

Adjuvant temozolomide therapy, following radiation, is standard for glioblastoma. The EORTC-NCIC CE.3 trial showed benefits of six cycles, though clinical practice often doubles this duration.

More Related Videos

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

Related Experiment Videos

Last Updated: May 26, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

Area of Science:

  • Neuro-oncology
  • Clinical Trials
  • Cancer Therapeutics

Background:

  • Adjuvant temozolomide following radiation is the standard of care for newly diagnosed glioblastoma.
  • The EORTC-NCIC CE.3 randomized phase III trial established the benefit of six cycles of adjuvant temozolomide.

Purpose of the Study:

  • To comment on variations in adjuvant therapy length for glioblastoma.
  • To compare clinical practice and national study protocols (e.g., RTOG 0825) with established trial data.
  • To contextualize these observations within historical adjuvant trials for solid tumors.

Main Methods:

  • Review of published clinical trial data (EORTC-NCIC CE.3, RTOG 0825).
  • Analysis of clinical practice patterns regarding adjuvant temozolomide duration.
  • Comparative analysis with historical adjuvant therapy trials in solid tumors.

Main Results:

  • The EORTC-NCIC CE.3 trial demonstrated the efficacy of six cycles of adjuvant temozolomide.
  • Significant differences exist in adjuvant therapy length between clinical practice and national studies, with some protocols doubling the duration seen in the CE.3 trial.
  • Historical adjuvant trials for solid tumors provide context for current glioblastoma treatment strategies.

Conclusions:

  • Six cycles of adjuvant temozolomide following chemoradiation remain the standard for newly diagnosed glioblastoma.
  • Discrepancies in adjuvant therapy duration warrant further investigation and potential standardization.
  • Understanding historical adjuvant trial outcomes informs ongoing research and clinical decision-making in glioblastoma treatment.